Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma

INTRODUCTION: Somatostatin analogues exert antitumour activity via direct and indirect mechanisms. The present study was designed to assess the safety and efficacy of pasireotide in patients with BRAF-wild type (WT) and NRAS-WT metastatic melanoma. PATIENTS AND METHODS: Patients with unresectable an...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:ESMO Open
Autores principales: Dummer, Reinhard, Michielin, Olivier, Nägeli, Mirjam Chantal, M. Goldinger, Simone, Campigotto, Federico, Kriemler-Krahn, Ulrike, Schmid, Herbert, Pedroncelli, Alberto, Micaletto, Sara, Schadendorf, Dirk
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6069912/
https://ncbi.nlm.nih.gov/pubmed/30094073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000388
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares